Lineage Cell Therapeutics, Inc. Common Stock · Operating Cash Flow (Statement)

Latest reported-$23.82Mperiod endingJun 30, 2026

LCTX Cash from Operations (-$600.00K → -$23.82M)

Annual operating cash flow (statement)

High-resolution chart · PNG

LCTX operating cash flow (statement) history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Operating Cash Flow (Statement) — Annual fiscal periods (USD)
Period ending	Operating Cash Flow (Statement) (USD)
Dec 31, 2025	-18,919,000
Dec 31, 2024	-23,092,000
Dec 31, 2023	-28,566,000
Dec 31, 2022	1,059,000
Dec 31, 2021	-23,561,000
Dec 31, 2020	-19,753,000
Dec 31, 2019	-31,947,000
Dec 31, 2018	-30,882,000
Dec 31, 2017	-30,517,000
Dec 31, 2016	-42,326,000
Dec 31, 2015	-44,544,000
Dec 31, 2014	-38,854,200
Dec 31, 2013	-29,508,613
Dec 31, 2012	-19,679,518
Dec 31, 2011	-13,593,916
Dec 31, 2010	-7,732,884
Dec 31, 2009	-4,259,938
Dec 31, 2008	-1,604,245
Dec 31, 2007	-1,239,980
Dec 31, 2006	-1,262,219
Dec 31, 2005	-1,414,148
Dec 31, 2004	-1,536,696
Dec 31, 2003	-654,144
Dec 31, 2002	-2,129,155
Dec 31, 2001	-3,209,834
Dec 31, 2000	-4,857,030
Dec 31, 1999	-4,394,901
Dec 31, 1998	-2,100,000
Jun 30, 1998	-1,300,000
Jun 30, 1996	-2,100,000
Jun 30, 1995	-2,000,000
Jun 30, 1994	-1,600,000
Jun 30, 1993	-1,300,000
Jun 30, 1992	-600,000